Papers: 10.1371/journal.pone.0230306

https://doi.org/10.1371/journal.pone.0230306

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

Cited by: 16
Author(s): Thomas DeLeon, Daniel Almquist, Benjamin R. Kipp, Blake T. Langlais, Aaron R. Mangold, Jennifer L. Winters, Heidi E. Kosiorek, Richard W. Joseph, Roxana S. Dronca, Matthew S. Block, Robert R. McWilliams, Lisa A. Kottschade, Kandelaria M. Rumilla, Jesse S. Voss, Mahesh Seetharam, Aleksandar Sekulić, Svetomir N. Markovic, Alan H. Bryce
Published: over 6 years ago

Software Mentions 1